Document:

Amended and Restated Agreement

 Exhibit 10.1 
 AMENDED AND RESTATED AGREEMENT 
 This Amended and Restated Agreement
(“Agreement”) effective as of January 1, 2011 (“Effective Date”) supersedes and replaces the Previous Agreement (as defined below), and is made by and between: 

Trimeris, Inc., 2530 Meridian Parkway, 2nd floor, Durham, North Carolina 27713 (“Trimeris”) on the one hand, and 

F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, CH-4070 Basel, Switzerland, and 
 Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110 on the other hand (collectively, “Roche”) 
 BACKGROUND 

WHEREAS, Trimeris and Roche (collectively the “Parties”) have
previously entered into (a) a Development and License Agreement (including its Appendices) dated as of the
1st day of July 1999, by and between Trimeris and Roche
(“Development and License Agreement”), as amended by the Amendment to the Development and License Agreement (“DLA First Amendment”) executed July 12, 2004 and rescinded and voided ab initio on July 12, 2004 by
the Rescission of the Amendment to the Development and License Agreement (“Rescission”) and the Letter of Amendment (“DLA Second Amendment”) effective September 20, 2005 (collectively, the Development and License Agreement,
the DLA First Amendment and the DLA Second Amendment, the “DLA”) and (b) a Research Agreement dated 

 
January 1, 2000, by and between Trimeris and Roche (“Research Agreement”), as amended by the First Amendment to the Research Agreement (“RA First Amendment”) effective as
of November 13, 2003, the Second Amendment to the Research Agreement (“RA Second Amendment”) effective as of December 31, 2005, and the Third Amendment to the Research Agreement and Accord (“RA Third Amendment”)
effective as of August 15, 2006 (collectively, the Research Agreement, the RA First Amendment, the RA Second Amendment and the RA Third Amendment, the “RA” and, together with the DLA, the “Previous Agreement”); and

 WHEREAS, the Parties have entered into the Agreement Relevant to the
Settlement and License Agreement dated as of the 23rd day
of September 2010 (“Novartis Settlement”) and this Agreement does not alter the terms or conditions of the Novartis Settlement; and 
 WHEREAS, the Parties have reached resolution on all disputes relating to the Previous Agreement (“Disputes”); and 

WHEREAS, the Parties want to settle these Disputes and enter into this Agreement to reflect the new
understanding between Trimeris and Roche. 
 NOW, THEREFORE, in
consideration of the foregoing premises and the covenants and obligations set forth in this Agreement, the Parties hereby agree as follows: 

ARTICLE 1 - DEFINITIONS 
 1.1
“Adjusted Gross Sales” shall mean the gross sales amount invoiced by Roche, its Affiliates, or sublicensees for the Product to non-Affiliated third party purchasers less, to the extent such amounts are included in the amount of gross

  
 -2-

 
sales invoiced and not otherwise recovered, deductions of returns (including withdrawals and recalls), rebates (price reductions, including Medicaid or performance based and similar types of
rebates e.g., chargebacks or retroactive price reductions), volume (quantity) discounts, discounts granted at the time of invoicing, sales taxes and other taxes directly linked to the gross sales amount as computed on a product-by-product basis in
Roche’s sales statistics for the countries concerned. 
 1.2 “Affiliate” shall mean: 

a) an organization fifty percent (50%) or more of the voting stock of which is owned and/or controlled directly or indirectly by a
Party to this Agreement; 
 b) an organization which directly or indirectly owns and/or controls fifty percent (50%) or
more of the voting stock of a Party to this Agreement; or 
 c) an organization which is directly or indirectly under common
control with a Party to this Agreement through common share holdings. 
 Anything to the contrary in this Section 1.2 notwithstanding,
Chugai Pharmaceutical Co., Ltd., a Japanese corporation, (“Chugai”) shall not be deemed an Affiliate of Roche unless Roche provides written notice to Trimeris of its desire to include Chugai as an Affiliate. 

1.3 “Claims” shall mean any and all claims, actions, causes of action, demands, suits, proceedings, administrative proceedings, losses,
damages, costs, expenses, liabilities, charges, interest, penalties, fines and charges of whatever nature (including costs of collection, attorneys’ fees and other legal expenses, costs of enforcing indemnifications provisions, and expenses of
investigation), whether known or unknown. 

  
 -3-

 1.4 “Compound” shall mean all compounds covered by the Trimeris Patents listed in Appendix A
including enfuvirtide which is the active ingredient in the Product sold under the brand name Fuzeon®. 
 1.5 “Dear Doctor Letter
Sharing Payment” shall mean one hundred thousand US dollars ($100,000), payable by Trimeris to Roche pursuant to Section 7.1(a) of this Agreement, which Trimeris has agreed to pay as a contribution toward costs incurred by Roche in
connection with a certain so-called “Dear Doctor Letter” issued by Roche with respect to the Product. 
 1.6 “Disputes”
shall mean any and all disputes relating to the Previous Agreement or the activities conducted in connection with the Previous Agreement, whether or not resulting in Claims. 
 1.7 “DLA” shall have the meaning set forth in the recitals above. 
 1.8 “FDA”
shall mean the Food and Drug Administration in the USA and equivalent governmental agencies outside the USA. 
 1.9 “Information”
shall mean any and all materials, trade secrets or other information related to the making, having made, using, offering for sale, selling or importing Product (including, without limitation, Technical Information and business information or
objectives) which is disclosed by one Party to the other Party, including any and all materials, trade secrets or other information related to the making, having made, using, offering for sale, selling or importing Product that was disclosed under
the Previous Agreement. 
 1.10 “Joint Invention” shall mean any invention (whether or not patentable) resulting from activities
arising under this Agreement or the Previous Agreement which was (a) conceived and reduced to practice by both Parties during the term of 

  
 -4-

 
the Previous Agreement or during the Term or (b) conceived by both Parties during the term of the Previous Agreement or during the Term and reduced to practice, by either or both Parties,
prior to twenty-four (24) months after the expiration or termination of this Agreement. 
 1.11 “Joint Patents” shall mean all
Patents claiming Joint Inventions, and all Patents claiming Trimeris Inventions or Roche Inventions which relate to improvements or modifications of Compound the practice of which would infringe a Valid Claim of a Trimeris Patent. 

1.12 “Launch of Product” shall mean, on a country-by-country basis, the first date on which a Product is or was shipped commercially by Roche
to an independent third party in a country, after formal marketing approval in that country, including any required price approval, has been granted from the relevant authority in that country for that Product. 

1.13 “NDA” shall mean a New Drug Application or Biological License Application filed with the FDA, or its foreign equivalent, for approval to
market and sell a drug or biological. 
 1.14 “Net Sales” shall mean Adjusted Gross Sales less a lump sum deduction of five and
one-half percent (5.5%) of Adjusted Gross Sales for those sales related deductions which are not accounted for on a product-by-product basis. 
 1.15 “Novartis Settlement” shall have the meaning set forth in the recitals above. 

1.16 “Parties” shall mean Trimeris and Roche and “Party” shall mean Trimeris or Roche, as appropriate, as defined above. 

  
 -5-

 1.17 “Past Settlement Amount” shall mean five million US dollars ($5,000,000), payable by Roche to
Trimeris pursuant to Section 7.1(a) of this Agreement, which is in full satisfaction and accord of all amounts due, payable or owing from Roche to Trimeris with respect to resolving any and all Disputes and Claims in connection with the
Previous Agreement. 
 1.18 “Patents” shall mean: 
 (a) patents and the patent applications relating to the subject matter of this Agreement, including 
 (b) all patents arising from said applications and all patents and patent applications based upon or claiming the priority date(s) of any of the foregoing; 

(c) any additions, divisions, continuations, continuations-in-part, amendments, amalgamations, reissues and re-examinations of such
applications or patents; 
 (d) any confirmation, importation and registration patents thereof or therefore; and 

(e) any extensions and renewals of all such patents and patent applications in whatever legal form and by whatever legal title they are
granted (e.g. supplementary protection certificates). 
 1.19 “Previous Agreement” shall have the meaning set forth in the recitals
above. 
 1.20 “Previous Agreement Effective Date” shall mean July 1, 1999. 

1.21 “Product” shall mean any pharmaceutical product which contains at least one Compound, including the Product sold under the brand name
Fuzeon®. 

  
 -6-

 1.22 “Roche Invention” means any invention (whether or not patentable) relating to the subject
matter of this Agreement which is (a) conceived and reduced to practice during the term of the Previous Agreement or during the Term solely by a person or persons contractually required to transfer (such as by assignment or license) patent
rights relating to such inventions to Roche or its Affiliates or (b) conceived during the term of the Previous Agreement or during the Term and reduced to practice prior to 24 months after the expiration or termination of this Agreement solely
by a person or persons contractually required to transfer (such as by assignment or license) patent rights relating to such inventions to Roche or its Affiliates. 
 1.23 “Technical Information” shall mean any and all technical data, information, materials including samples of Product, chemical manufacturing data, toxicological data and pharmacological data,
clinical data, medical uses, formulations, specifications, quality control testing data, and all submissions and correspondence to and from the FDA with regard to Product made by or on behalf of Trimeris or its Affiliates, which is reasonably useful
to enable Roche to make, have made, use, offer for sale, sell or import Product. 
  

	1.24	“Term” shall mean the time period set forth in Section 10.1 of this Agreement. 

 1.25 “Trimeris Invention” means any invention (whether or not patentable) relating to the subject matter of this Agreement which is (a) conceived and reduced to practice during the term of
the Previous Agreement or during the Term solely by a person or persons contractually required to transfer (such as by assignment or license) patent rights relating to such inventions to Trimeris or its Affiliates or (b) conceived during the
term of the Previous Agreement or during the Term and reduced to practice prior to twenty-four (24) months after the expiration or termination of this Agreement solely by a person or persons contractually required to transfer (such as by
assignment or license) patent rights relating to such inventions to Trimeris or its Affiliates. 

  
 -7-

 1.26 “Trimeris Know-how” shall mean all know-how (including Technical Information) owned by or
licensed (with the right to grant sublicenses) to Trimeris on the Effective Date or at any time during the term of the Previous Agreement or during the Term, relating to the making, having made, using, offering for sale, selling and importing of a
Compound and a Product. 
 1.27 “Trimeris Patents” shall mean (a) all Patents owned by or licensed (with the right to grant
sublicenses) to Trimeris as of the Previous Agreement Effective Date. Such Trimeris Patents include all those patents and patent applications as set forth in Appendix A; and (b) all Patents acquired by Trimeris after the Previous Agreement
Effective Date which Trimeris, in its sole discretion, and subject to Roche’s agreement, chooses to include within the scope of this Agreement. Trimeris, from time to time, but not less than once a year during the Term of this Agreement shall,
if there are any changes, update Appendix A and provide the updated Appendix A to Roche. 
 1.28 “Trimeris Proprietary Rights” shall
mean (i) the Trimeris Patents and (ii) the Trimeris Know-how. 
 1.29 “Valid Claim” means a claim in any unexpired and
issued patent or patent application of Trimeris Patents that has not been disclaimed, revoked or held invalid by a final unappealable decision of a court of competent jurisdiction, and which claim, if issued, is otherwise enforceable. 

 

	2.	SETTLEMENT OF PAST DISPUTES 

 2.1
The Parties hereby rescind the Previous Agreement as of the Effective Date. 

  
 -8-

 2.2 No payments are due, owing or payable by Roche to Trimeris or by Trimeris to Roche under the Previous
Agreement. For the avoidance of doubt, royalties shall be payable under, and subject to the terms of, this Agreement on worldwide Net Sales occurring from and after January 1, 2011. 
 2.3 Trimeris, acting on behalf of itself and its predecessors, successors, assigns, and Affiliates (Trimeris and its predecessors, successors, assigns, and Affiliates collectively the “Trimeris
Releasors”), does hereby now and shall forever release and discharge Roche, their predecessors, successors, assigns and Affiliates, and each of their respective current and former officers, directors, employees, agents, attorneys,
representatives, distributors, resellers, licensees, and direct or indirect customers (collectively and individually, “Roche Releasees”), from and against any and all Claims relating to the Prior Agreement or the activities conducted in
connection with the Prior Agreement arising before the Effective Date other than third party claims that are subject to Roche’s indemnification obligations under the Prior Agreement, as to which Roche shall remain obligated to indemnify, defend
and hold harmless the Trimeris indemnified parties in accordance with the indemnification provisions of the Prior Agreement. 
 2.4 Roche,
acting on behalf of itself and its respective predecessors, successors, assigns, and Affiliates (Roche and its predecessors, successors, assigns, and Affiliates collectively the “Roche Releasors”), does hereby now and shall forever release
and discharge Trimeris, and each of its respective predecessors, successors, assigns and Affiliates, and each of its respective current and former officers, directors, employees, agents, attorneys, and representatives, distributors, resellers,
licensees, and direct or indirect customers (collectively and individually “Trimeris Releasees”), from and against any and all Claims relating to the Prior Agreement or the activities conducted in connection with the Prior Agreement
arising before the Effective Date, as to which Trimeris shall remain obligated to indemnify, defend and hold harmless the Roche indemnified parties in accordance with the indemnification provisions of the Prior Agreement. 

  
 -9-

 2.5 Neither any Trimeris Releasor nor any Roche Releasor shall now or at any time in the future initiate any
arbitration, lawsuit or other proceeding asserting (or otherwise assert, directly or through any third party) any Claim released pursuant to Sections 2.3 or 2.4 of this Agreement. For the avoidance of doubt, nothing herein shall be construed to
release Roche from its obligation to pay the Past Settlement Amount in accordance with Section 7.1(a) or royalties in accordance with Section 7.1(b) or to release Trimeris from its obligation to pay the Dear Doctor Letter Sharing Payment
in accordance with Section 7.1(a). If any Trimeris Releasor breaches any obligation set forth in Section 2.3, then the Trimeris Releasor shall indemnify each Roche Releasee, and defend and hold each such Roche Releasee harmless, from and
against Claims arising out of or related to such breach. If any Roche Releasor breaches any obligation set forth in Section 2.4, then the Roche Releasor shall indemnify each Trimeris Releasee, and defend and hold each such Trimeris Releasee
harmless, from and against any Claims arising out of or related to such breach. This Section 2.5 will be fully enforceable in every respect, at law or in equity, by any non-Party Trimeris Releasee or non-Party Roche Releasee as an intended
third party beneficiary hereunder. 
 2.6 The Parties acknowledge that there is risk that after the Effective Date, they will discover, incur or
suffer Claims that are related to, or arise from facts connected with, the matters released under Sections 2.3 and 2.4 above, and arose in any way, in whole or in part, before the Effective Date, and that were unknown or unanticipated as of the
Effective Date (collectively, the “Unknown Claims”). Nonetheless, to the extent that a Party or any of its Affiliates is located or has operations in California, to the full extent permitted by applicable law, each of Party hereby waives,
relinquishes and discharges any and all Unknown Claims, and waives, relinquishes and discharges any and all rights it may have with respect to any Unknown Claims, including any rights provided by California Civil Code § 1542 (and similar
provisions in other jurisdictions), which provides: 
 A general release does not extend to claims which the creditor does not
know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor. 

  
 -10-

 2.7 Neither Party shall be permitted to audit any records for periods prior to the Effective Date.

 2.8 This Agreement shall in no way affect the Novartis Settlement. 
 2.9 The Parties acknowledge that as of the Effective Date, all payments due, owing or payable under the Prior Agreement shall be considered fully paid up. Neither Party shall owe any compensation or other
consideration (including but not limited to profit or loss, royalties, development event payments, marketing, COGS, sales milestones, negative cost variances, idle capacity charges, manufacturing costs, pre-launch inventory carrying costs, capital
contributions, write-offs, equipment value, cost variances, and other milestones), to the other Party based on any activity conducted under the Previous Agreement up to and including the Effective Date. 

2.10 Subject to the provisions of Article 10, nothing contained herein shall impact the ownership of the NDA for Product being owned by Roche or its
Affiliates, and all data generated in the development of Product shall continue to be jointly owned by Roche and Trimeris and shall not be provided to any third party without the consent of both Parties. Notwithstanding the above, Roche shall have
the right to provide to a third party manufacturer whatever information and data is necessary to enable such third party manufacturer to manufacture and supply Product. 

  
 -11-

	3.	GRANT OF RIGHTS 

 3.1 License
Grant. Trimeris grants Roche a worldwide, sole and exclusive right and license, with the right to sublicense (except as set forth in Section 3.2), to make and have made, use, offer for sale, import and sell Compounds and Products under the
Trimeris Proprietary Rights and Trimeris’ part of the Joint Patents. 
 The sole and exclusive license with regard to a Product hereunder
shall become non-exclusive on a country-by-country basis at the later of (i) the expiry of the last Valid Claim of Trimeris Patents in such country or (ii) twelve (12) years after the Launch of Product in such country. For the purpose
of this Section 3.1 the European Union shall be considered as one country. 
 Notwithstanding the foregoing, Trimeris shall have the right
to grant licenses to third parties for Compounds and Products other than the Compound enfuvirtide and the Product sold under the brand name Fuzeon® in indications other than the treatment of HIV. In the event that Trimeris has granted such
license(s) at the time that when such Compound(s) or Product(s) start to be developed by Roche, the rights and licenses to Roche under this Agreement with regard to such Compound(s) and Product(s) shall be limited to a field consisting of the
treatment of HIV. 
 3.2 Sublicenses. Roche shall have the right to sublicense the rights granted under Section 3.1 above to any
given third party. 
 If Roche grants a sublicense, all of the terms and conditions of this Agreement shall apply to the sublicensee to the same
extent as they apply to Roche for all purposes. Roche assumes full responsibility for the performance of all obligations so imposed on such sublicensee and will itself pay and account to Trimeris for all payments due under this Agreement by reason
of the operation of any such sublicenses. 

  
 -12-

	4.	DILIGENCE AND DATA OWNERSHIP 

 4.1.
Due Diligence. Roche shall use best efforts consistent with prudent business practices to maintain necessary governmental approval to market the Product sold under the brand name Fuzeon®. “Best efforts” with regard to Roche
under this Section 4.1 shall mean the standard of effort consistent with the efforts major pharmaceutical companies devote to significant specialty products of similar market potential derived from internal research programs. 

4.2 NDA. The NDA for Product shall be owned by Roche or its Affiliates. 
 4.3 Data. All data generated on account of the development program under the Previous Agreement shall be owned jointly by Roche and Trimeris and shall not be provided to any third party without the
consent of both Parties. 
  

	5.	SUPPLY AND MANUFACTURING 

 Roche
shall be fully responsible for all supply and manufacturing of Product. Trimeris shall have no say with regard to Roche’s supply and manufacturing efforts. Trimeris shall have no say with regard to Roche’s handling, maintenance or
divestiture of its Boulder, Colorado manufacturing facility, and Trimeris has no financial or decision making rights with regard to such manufacturing facility. 
  

	6.	COMMERCIALIZATION 

 6.1 Due
Diligence. Roche shall use best efforts consistent with prudent business practices to market and sell Product sold under the brand name Fuzeon® in the top eight (8) major countries of the world as determined by market size for HIV and

  
 -13-

 
AIDS drugs. Best efforts for Roche under this Section 6.1 shall mean the standard of effort consistent with the efforts major pharmaceutical companies devote to specialty products of similar
market potential and lifecycle phase. 
 6.2 Trademarks. Roche shall own the trademarks for a given Product and Roche shall bear the cost
of obtaining and maintaining such trademarks. 
 6.3 Use of the Trimeris Name. The packaging and promotional materials for the Products
marketed by Roche and/or Roche’s sublicensees shall identify Trimeris as licensor. If only one name is allowed to be in any specific item of packaging or promotional material pursuant to governmental laws or regulations, then Roche may use its
name alone on such item, without identifying Trimeris as licensor. 
 6.4 Reports; Notice of Material Changes; Inquiries. In addition to
the Net Sales reports provided by Roche to Trimeris pursuant to Section 7.1(d), Roche shall provide Trimeris with a reasonable written summary of Roche’s efforts to market and sell the Product worldwide within forty-five (45) days
after the end of each calendar year. Roche shall also make good faith efforts to promptly (and, if practicable under the circumstances, in advance) notify Trimeris of any material changes to Roche’s marketing and sales of the Product. On a
quarterly basis, within thirty (30) days after Roche provides each quarterly royalty report for the prior calendar quarter to Trimeris as required under Section 7.1(d), Roche and Trimeris shall conduct a telephone conference in which,
among other representatives that the Parties may elect to have participate, the applicable Roche marketing representatives, the applicable Roche Alliance Director and the applicable Roche Finance Director shall participate for Roche and the Chief
Executive Officer of Trimeris shall participate for Trimeris, in order to provide Trimeris with an opportunity to discuss with Roche questions and concerns that Trimeris may have regarding Roche’s marketing and sales of the Product and Roche
shall make good faith efforts to provide reasonable responses to queries presented by Trimeris during such calls, including without limitation such queries that Trimeris may present with respect to information underlying Roche’s royalty reports
and calculation of Net Sales. 

  
 -14-

	7.	CONSIDERATION 

 7.1 Payments

 (a) Past Settlement Amount; Dear Doctor Letter Sharing Payment. Within ten (10) days after the signing of this
Agreement by both Parties, Roche shall pay to Trimeris the Past Settlement Amount and Trimeris shall pay to Roche the Dear Doctor Letter Sharing Payment. Trimeris’ payment of the Dear Doctor Letter Sharing Payment shall be made by an offset to
be taken by Roche against Roche’s payment of the Past Settlement Amount (i.e., Roche shall pay to Trimeris a net payment of $4,900,000, and upon such payment by Roche, Roche’s obligation to pay the Past Settlement Amount and Trimeris’
obligation to pay the Dear Doctor Letter Sharing Payment shall be satisfied). 
 (b) Royalties for Product. For sales of
Product beginning on the Effective Date, Roche shall pay to Trimeris a royalty equal to sixteen percent (16%) of worldwide Net Sales of Product. 
 (c) Duration. The royalty obligation under Section 7.1(b) shall, on a country-by-country basis continue for the longer of (i) twelve (12) years from Launch of Product in that country
or (ii) the date of the last to expire Valid Claim of the Trimeris Patents which, but for this Agreement, would be infringed by Roche’s making, having made, using, importing, offering for sale or selling Product in that country.

 (d) Report. Within forty-five (45) days after the end of each calendar quarter, Roche shall provide Trimeris with
a report of Net Sales of Product sold on a 

  
 -15-

 
country-by-country basis by Roche for that calendar quarter, and compute the amount of royalties owed by Roche to Trimeris under this Section 7.1. Payment of such royalties shall be made
within sixty (60) days after the end of each calendar quarter. 
 7.2 Withholding Tax. All payments under Section 7.1 shall be
made in full without deduction of taxes, charges or any other duties that may be imposed, provided, however, that Roche shall to the extent required under the tax law of a given country, withhold withholding taxes from any such sum and forthwith
upon paying such sum to the given country’s tax authorities promptly furnish Trimeris with the receipt thereof in respect of the same. The Parties agree to cooperate in all respects necessary to (a) take advantage of reduced withholding
tax rates available under any applicable tax treaties, and (b) assist Trimeris in obtaining any refunds for Trimeris of amounts withheld and paid to tax authorities. 
 7.3 Third Party Payments. If Roche, in good faith, pays consideration under patent rights or know-how owned or controlled by a non-Affiliate third party, which in Roche’s opinion, is
reasonably required to allow Roche to make, have made, use, import, offer for sale or sell Product in a given country, Roche may deduct fifty percent (50%) of such consideration from the royalty payments by Roche to Trimeris under this
Agreement. For the avoidance of doubt and subject to the foregoing limitation, Roche may deduct fifty percent (50%) of payments to Novartis under the terms of the Novartis Settlement. 
 Other than payments to Novartis under the terms of the Novartis Settlement, Trimeris shall be solely responsible for all royalties and other payments that may be due or payable by Trimeris under
agreements between Trimeris and third parties, during the Term, including any payments that may become due under agreements entered into by Trimeris subsequent to the Effective Date. Subject to the provisions of Section 9.4, Roche shall
reimburse Trimeris for such payments made by Trimeris 

  
 -16-

 
which are reasonably required to make, have made, use import, offer for sale or sell Product in a given country, provided that Roche may deduct fifty percent (50%) of such reimbursement from
the royalty payable by Roche to Trimeris under this Agreement. 
 However, in no event shall any such royalty payment to Trimeris be reduced by
more than fifty percent (50%) in aggregate in any quarter as a result of all reductions pursuant to this Section 7.3, with any amounts not utilized as a result of such limitation being carried forward to future reporting periods.

 7.4 Royalties Due Once. Sales of Product between and among Roche, its Affiliates and its sublicensees shall not be subject to a
royalty. The obligation to pay royalties to Trimeris under this Agreement is imposed only once with respect to the same unit of Product. 
 7.5
Combination Products. For any product containing both a pharmaceutically active agent which causes it to be considered a Product and one or more other pharmaceutically active agents which are not Products (“Combination Product”),
the Parties shall in good faith negotiate and agree to an appropriate adjustment to the Net Sales to reflect the relative contribution of each Product and each other pharmaceutically active agent which is not a Product to the Combination Product.
If, after good faith negotiations (not to exceed ninety (90) days, which can be extended by mutual agreement), the Parties cannot agree to an appropriate adjustment, Net Sales shall be equal to Net Sales of the Combination Product multiplied by
a fraction, the numerator of which is the reasonable fair market value of the Compounds contained in the Combination Product and the denominator of which is the reasonable fair market value of all pharmaceutically active agents contained in the
Combination Product. 

  
 -17-

 7.6 Currency Conversion. When calculating the Net Sales for countries other than the United States of
America, Roche shall convert the amount of such sales in currencies other than Swiss Francs into Swiss Francs as computed in Roche’s central Swiss Francs Sales Statistics for the countries concerned, using the internal foreign currency
translation Roche’s then current standard practices actually used on a consistent basis in preparing its audited financial statements. After converting the amount of Net Sales into Swiss Francs, Roche shall convert the amount into US
Dollars, using the year to date average exchange rate for the applicable royalty period in accordance with Roche’s then current standard practices. 
 7.7 Blocked Country. If at any time a Product is sold in a country in which conditions or legal restrictions exist which prohibit remittance of USD or Swiss Francs (“Blocked Country”) the
following provisions shall apply to the payment of the corresponding royalty, depending on where the Product is made: 
 (a) If
such Product is made in the same or another Blocked Country, Roche shall make such royalty payment by depositing the amount thereof in the currency of the country of sale or manufacture, at Trimeris’ election, to Trimeris’ account in a
bank designated by Trimeris in such country. 
 (b) If such Product is made in a country which is not a Blocked Country, then a
“number” shall be obtained by multiplying the applicable royalty rate by the price at which the Product is sold to the entity selling in the Blocked Country. Roche or its Affiliate (i) shall pay that “number” to Trimeris as
converted to USD in accordance with Section 7.6, and (ii) shall deposit the excess of the applicable royalty over the “number”, in the currency of the country of sale of the Product, to Trimeris’ account in a bank designated
by Trimeris in such Blocked Country. 
 7.8 Audit. Roche shall keep, and shall require its Affiliates and sublicensees to keep, accurate
and correct records of Products sold under this Agreement after the Effective Date appropriate to determine the amounts due hereunder to Trimeris. Such records shall be retained for at least three (3) years following the end of the calendar
year to which such records pertain. 

  
 -18-

 At Trimeris’ request, Roche will cause its independent certified public accountants to prepare
abstracts of Roche’s relevant business records for review by Trimeris. If, based upon a review of such abstracts, Trimeris reasonably believes that a full audit of said business records would be necessary for the confirmation of the accuracy of
all payments due hereunder, Trimeris shall have the right to engage Roche’s independent public accountant to perform, on behalf of Trimeris, an audit of all work papers and supporting documents pertinent to such abstracts. 

The audit rights under this Agreement may be exercised by Trimeris (i) no more often than once per calendar year, (ii) not more frequently than
once with respect to records covering any specific period of time, and (iii) no later than three (3) years after the end of the payment period to which such records relate, provided that once Trimeris requests an abstract of Roche’s
relevant business records, such three (3) year period shall be tolled during the period that it takes for Roche’s independent certified public accountants to prepare such abstracts and the date of Trimeris’ notice to Roche of
Trimeris’ exercise of such audit rights shall be deemed to be the date of exercise by Trimeris. The audit shall be performed upon no less than thirty (30) days prior written notice to Roche, during Roche’s normal business hours. The
terms of this Section 7.8 shall survive the Term for a period of three (3) years. 
 Trimeris will bear the full cost of any such
abstracts or audit unless such audit discloses an underpayment to Trimeris of more than five percent (5%) from the amounts paid. Roche shall promptly (i) pay any underpayment due to Trimeris and, (ii) if the underpayment is more than
five percent (5%) of the amount paid, Roche shall bear the full reasonable cost of such audit. Any overpayment by Roche shall be deducted from the next payment due Trimeris under Section 7 of this Agreement or, if no such further payments
are due, promptly reimbursed to Roche by Trimeris. 

  
 -19-

 7.9 Mechanism for Adjustment. Should any amount such as reductions, credits or deductions otherwise
allowable to Roche for a country under this Agreement not be utilized by Roche upon the termination of this Agreement, then Trimeris shall promptly reimburse Roche for the allowable amount. 

 

	8.	INFORMATION 

 8.1 Exchange.
Following the Effective Date, Trimeris shall make available to Roche all Trimeris Proprietary Rights which have not been disclosed to Roche until the Effective Date. 
 During the Term, the Parties will, free of charge, exchange and, to this end, the Parties shall establish a mechanism by which the Parties will share, Information necessary for the Parties to meet their
obligations under this Agreement. 
 In particular, a Party shall, to the extent it is legally permitted to do so, exchange all information
coming into its possession or control, or its representatives or Affiliates possession or control, relating to formulation, manufacture, improvement, use and sale of Product, including any such information consisting of technical, pharmacological,
preclinical, clinical, biochemical, toxicological and pharmacokinetic experimental data and results related to Product. Each Party shall also permit a reasonable number of representatives of the other Party or its Affiliates, at reasonable time and
upon reasonable notice, to observe, review, make copies of, and/or discuss with the Party or its Affiliate’s scientists and/or clinicians supervising or conducting research related to Product, the results of studies and/or submissions to
governmental agencies concerning Products, at mutually agreeable times and locations. Each Party shall also permit a reasonable number of representatives of 

  
 -20-

 
the other Party or its Affiliates, at reasonable time and upon reasonable notice, to observe, review, make copies of, and/or discuss with its or its Affiliate’s scientists supervising or
conducting manufacture of Product or third party scientists supervising or conducting manufacture on behalf of it, at mutually agreeable times and locations. 
 8.2 Information. During the Term and for five (5) years after termination, a Receiving Party shall a) treat Information provided by a Disclosing Party as it would treat its own information of
a similar nature and take all reasonable precautions not to disclose such Information to third parties except Affiliates or actual or potential sublicensees who agree to be bound by the same terms and conditions as found in this Article 8, without
the other Party’s prior written authorization and b) not use such Information for other than the purposes of fulfilling its obligations under this Agreement. 
 The provisions of this Section 8.2 shall not apply to such Information which: 

(a) was known or used by the Receiving Party or its Affiliates prior to its date of disclosure to the Receiving Party or its Affiliates
by the Disclosing Party or its Affiliates, as evidenced by the prior written records of the Receiving Party or its Affiliates; or 
 (b) either before or after the date of the disclosure to the Receiving Party or its Affiliates, is lawfully disclosed to the Receiving Party or its Affiliates by a third party rightfully in possession of
such information; or 
 (c) either before or after the date of the disclosure to the Receiving Party or its Affiliates, becomes
published or generally known to the public through no fault or omission on the part of the Receiving Party or its Affiliates, but such inapplicability applies only after such information is published or becomes generally known; or 

  
 -21-

 (d) is independently developed by the Receiving Party or its Affiliates without reference to
or reliance upon any such information of the Disclosing Party or its Affiliates; or 
 (e) is required to be disclosed by the
Receiving Party or its Affiliates to comply with applicable laws, to defend or prosecute litigation or to comply with governmental regulations, provided that, the Receiving Party or its Affiliates provides prior written notice of such
disclosure to the Disclosing Party or its Affiliates and, to the extent practicable, takes reasonable and lawful actions to avoid and/or minimize the degree of such disclosure. 
 8.3 Publications. During the Term of the Agreement, the following restrictions shall apply with respect to disclosure by any Party of Information in any publication or presentation (collectively
“Publications”): 
 (a) A Party (“Publishing Party”) shall provide the other Party with a copy of any
proposed Publication at least forty-five (45) days or less if agreed by both Parties prior to submission for publication so as to provide such other Party with an opportunity to recommend any changes it reasonably believes are necessary to
continue to maintain the Information disclosed by the other Party to the Publishing Party in accordance with the requirements of this Agreement. The incorporation of such recommended changes shall not be unreasonably refused; and 

(b) If such other Party notifies (“Notice”) the Publishing Party in writing, within forty-five (45) days of receipt of the
copy of the proposed Publication, that such Publication in its reasonable judgment (i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, for which the other Party reasonably desires to obtain
patent protection or (ii) could be expected to have a material adverse effect on the commercial value of any Information disclosed by the 

  
 -22-

 
other Party to the Publishing Party, the Publishing Party shall prevent such publication or delay such publication for a mutually agreeable period of time. In the case of inventions, a delay
shall be for a period reasonably sufficient to permit the timely preparation and filing of a patent application(s) on the Invention, and in no event less than one hundred and eighty (180) days from the date of Notice. In the event the Parties
do not agree as to whether such Publication (i) contains an invention, solely or jointly conceived and/or reduced to practice by the other Party, or (ii) could be expected to have a material adverse effect on the commercial value of any
Information disclosed by the other Party to the Publishing Party, either Party may submit the matter to arbitration generally in accordance with the procedures set forth in Article 12 of this Agreement. 

8.4 Exceptions. The restrictions set forth in this Article 8 shall not prevent either Party from (i) preparing, filing, prosecuting or
maintaining a patent application or its resulting patents related to the making, having made, using, offering for sale, selling or importing of Product, (ii) disclosing Information provided by the Disclosing Party to persons working on behalf
of the Receiving Party or to governmental agencies, to the extent the Receiving Party reasonably believes is required or desirable to secure any government approval for the development, manufacture, marketing or sale of Product, or (iii) upon
imminent approval or actual approval for Regulatory Approval by a governmental agency in a country of a drug application on Product, disclosing Information to the extent reasonably necessary to promote the use and sale of Product in the country.

 8.5 Adverse Events. Roche shall be responsible for reporting to the appropriate regulatory authorities all adverse events related to
the use of the Products worldwide. Adverse events related to the use of the Products worldwide shall be recorded in Roche’s standard database. 

  
 -23-

	9.	PATENTS 

 9.1 Ownership of
Technology. 
 (a) Trimeris Proprietary Rights. Subject to Section 9.1(b), ownership of Trimeris Proprietary
Rights and other intellectual property owned or controlled by Trimeris shall remain vested at all times in Trimeris. 
 (b)
Joint Patents. Ownership of Joint Patents shall be vested jointly in Trimeris and Roche. 
 9.2. Patent Filing, Prosecution and
Maintenance. 
 (a) Trimeris Patents. Subject to Section 9.2(b) and the further provisions of this
Section 9.2(a), Trimeris agrees to (i) prepare, file, prosecute and maintain all Trimeris Patents in such countries as may be determined by the Parties, (ii) consult with Roche as to the preparing, filing, prosecuting and maintaining
of such patent applications and patents, and (iii) furnish to Roche copies of all significant documents relevant to any such preparation, filing, prosecution or maintenance. Trimeris shall furnish such documents and consult with Roche in
sufficient time before any action by Trimeris is due to allow Roche to provide comments thereon, which comments Trimeris shall consider. Trimeris shall bear all costs and expenses for preparing, filing, prosecuting and maintaining such patents and
patent applications. Roche shall cooperate, in all reasonable ways and at Trimeris’ cost, in connection with the preparing, filing, prosecuting and maintaining Trimeris Patents, each Party to absorb its own expenses related thereto. Should
Trimeris decide that it does not desire to file, maintain or prosecute any Trimeris Patent in one or more countries, it shall promptly advise Roche thereof and, at the request of Roche, Trimeris shall (i) in the case of Trimeris Patents which
are owned by Trimeris, assign to Roche its rights in and to such patent or patent application in such country or countries, or (ii) in the case of Trimeris Patents which are licensed, provide Roche with such rights to prosecute and maintain
such patent or patent application as may be permitted, and Roche will thereafter file, prosecute and/or maintain the same at Roche’s own cost, to the extent that Roche desires to do so. 

  
 -24-

 (b) Joint Invention, Trimeris Inventions and Roche Inventions. As soon as a Party
concludes that it wishes to file a patent application claiming a Joint Invention, Trimeris Invention and Roche Invention, it shall immediately inform the other Party. The Party also will provide the other Party with the determination of inventors
and a copy of a draft specification, if any, and the scope of claims as early as possible. Unless otherwise agreed, Roche agrees to (i) prepare, file, prosecute and maintain such priority patent application, corresponding foreign patents, and
resulting patents, (ii) consult with Trimeris as to the preparing, filing, prosecuting and maintaining of such patent applications and resulting patents, and (iii) furnish Trimeris with copies of all documents relevant to any such
preparation, filing, prosecution or maintenance. Unless agreed otherwise, the filing Party shall furnish such documents and consult with the other Party in sufficient time before any action by the filing Party is due to allow the other Party to
provide comments thereon, which comments the filing Party shall consider. All external costs and expenses for preparing, filing, prosecuting and maintaining such patent applications and resulting patents shall be borne by Roche. Each Party shall
bear its own internal costs. On request of the Party performing the filing, the other Party will cooperate, in all reasonable ways, in connection with the preparing, filing, prosecuting and maintaining of such patent applications and resulting
patents. Should the filing Party decide that it does not desire to file, maintain or prosecute a patent or patent application claiming a Joint Invention, Trimeris Invention or Roche Invention in one or more countries, it shall promptly advise the
other Party thereof and, at the request of the other Party, the filing Party shall assign to the other Party its rights in and to such patent or patent application in such country or countries, and the other Party will thereafter file, prosecute
and/or maintain the same at the other Party’s own cost, to the extent that the other Party desires to do so. 

  
 -25-

 9.3 Infringement by Third Parties. 

(a) Notification. Each Party shall promptly notify the other in writing of any alleged or threatened infringement of the
Trimeris Patents and Joint Patents, of which it becomes aware. 
 (b) Trimeris Patents. Trimeris shall have the
right, but not the obligation, to bring, at Trimeris’ expense and in its sole control, an appropriate action against any person or entity infringing a Trimeris Patent directly or contributorily. If Trimeris does not bring such action within
ninety (90) days (twenty (20) days in the case of an action brought under the Hatch-Waxman Act (or any foreign equivalent)) of notification thereof to or by Roche, Roche shall have the right, but not the obligation, to bring at
Roche’s expense and in its sole control, such appropriate action. The Party not bringing an action under this paragraph (b) shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense,
but such Party shall cooperate fully with the Party bringing such action. 
 (c) Joint Patents. With respect to
third party infringement of Joint Patents, the Parties shall confer and take such action, and allocate expenses and recoveries in such manner, as they may agree. In the absence of agreement within ninety (90) days of notification thereof, Roche
shall have the right, but not the obligation, to bring, at Roche’s expense and in its sole control, an appropriate action against any person or entity infringing a Joint Patent directly or contributorily. Trimeris shall have the right to be
fully informed regarding any litigation brought thereunder by Roche, including the status of any settlement activity. Notwithstanding anything herein to the contrary, should a Party receive a certification for a Product pursuant to the Drug Price
Competition and Patent Term Restoration Act of 1984 (Public Law 98-417), as amended, or its equivalent in a country other than the United States of America, then such Party shall immediately provide the other Party with a copy of such certification.
Trimeris shall have thirty (30) days from date on which it receives or 

  
 -26-

 
provides a copy of such certification to provide written notice to Roche (“H-W Suit Notice”) whether Trimeris will bring suit, at its expense, within a forty-five (45) day period
from the date of such certification. Should such thirty (30) day period expire without Trimeris bringing suit or providing such H-W Suit Notice, then Roche shall be free to immediately bring suit in its name. 

(d) Costs and Awards. The Party which is not in control of any action brought pursuant to Section 9.3(b) or
(c) may elect to contribute fifty percent (50%) of the costs of litigation against such third party infringer, by providing written notice to the controlling Party within ninety (90) days after such action is first brought. If the
non-controlling Party elects to bear fifty percent (50%) of such litigation costs, it shall receive fifty percent (50%) of any damage award or settlement resulting from such action. If the non-controlling Party does not elect to share such
litigation costs, it shall not participate in any damage award or settlement resulting from such action. 
 (e) Settlement;
Allocation of Proceeds. Neither Party shall settle a claim brought under this Section 9.3 without the consent of the other Party. In the event of any recovery of monetary damages from the third party, whether such damages result from
the infringement of Trimeris Patents or Joint Patents, such recovery shall be allocated first to the reimbursement of any expenses incurred by the Parties in the litigation under this Section 9.3 (including, for the purpose, a reasonable
allocation of internal counsel and other expenses), and thereafter as provided in Section 9.3(d). If the amount recovered from the third party is less than the aggregate expenses of the Parties incurred in connection with such litigation, the
recovery shall be shared pro rata between Trimeris and Roche in proportion to their respective expenses. 
 9.4 Infringement of Third Party
Rights. In the event that a third party at any time provides notice to, or commences an action, suit or proceeding against, a Party or 

  
 -27-

 
such Party’s Affiliates, sublicensees or distributors, claiming infringement of the third party’s patent rights or copyrights or unauthorized use or misappropriation of its technology,
based upon an assertion or claim arising out of the making, having made, using, offering for sale, selling or importing of a Product, such Party shall promptly notify the other Party. Neither Party may settle such claim or action without the consent
of the other Party. The Parties shall also discuss how the expenses and any recoveries from such action should be treated. If the Parties do not reach agreement, Roche shall make the final decision at its own discretion and expenses. 

 

	10.	TERM AND TERMINATION 

 10.1
Term. The Term shall commence on the Effective Date and, unless sooner terminated as provided in this Article, expire on a country-by country basis on the expiration of Roche’s payment obligations set forth in Section 7.1.

 After expiration, Roche shall have a fully paid up non-exclusive license under Trimeris Proprietary Rights, on a country-by-country basis.

 10.2 Termination. Roche shall have the right to terminate this Agreement on a country-by-country basis and on a Product-by-Product
basis by providing Trimeris with the following prior written notice: 
 (a) If Roche has launched Product in the given country, one
(1) year’s notice period; or 
 (b) If Roche has not launched Product in the given country, one hundred eighty days’
(180) notice period. 
 Termination shall be effective at the end of the applicable notice period. 

  
 -28-

 10.3 Material Breach. In the event of a material breach of this Agreement by either Party, the
non-breaching Party shall have the right to terminate this Agreement by providing written notice of such breach to the breaching Party, specifying the nature of such breach (“Breach Notice”). The non-breaching Party shall thereupon have
the right to terminate this Agreement immediately upon written notice if the breaching Party fails to cure such breach within sixty (60) days after receipt of the Breach Notice. 
 10.4 Effect of Termination. 
 (a) By Roche Without Cause.
Termination of this Agreement by Roche under Section 10.2 shall not relieve either Party of the performance of any obligations incurred or payments due prior to the effective date of termination. 

In the event of termination of this Agreement by Roche under Section 10.2, with regard to such country or Product (i) all licenses granted by
Trimeris to Roche shall terminate, (ii) at the request of Trimeris, Roche shall assign to Trimeris all regulatory filings, regulatory approvals and clinical data owned and controlled by Roche relating to Products, or, if such assignment is not
legally permissible, grant Trimeris the right to access, use and cross reference such filings, approval and data, and (iii) Roche shall, at its discretion, assign to Trimeris all rights in or grant to Trimeris an exclusive license to the
trademarks referred to in Section 6.2. 
 (b) By Either Party for Cause. Termination of this Agreement by either
Party under Section 10.3 shall (i) not relieve either Party of the performance of any obligations incurred or payments due prior to the date of breach, and (ii) be without prejudice to any remedy that any Party may have in addition to
those rights as provided under this Agreement. 
 (c) By Roche for Cause. In the event of termination of the Agreement by
Roche under Section 10.3, the rights and licenses granted by Trimeris to Roche 

  
 -29-

 
under this Agreement shall, at Roche’s option, remain in effect. If Roche chooses for such rights and licenses to remain in effect, Roche’s payment obligations under Article 7 shall
continue; provided, however, that the amounts of such payments shall be decreased to reflect the following factors: the nature of Trimeris’ breach, the damage to Roche caused thereby, and the relative contributions of the Parties to the
development of Product. Such amounts shall be determined by the mutual agreement of the Parties after good faith negotiations; provided, however, that if the Parties are unable to reach mutual agreement thereon, the matter shall be submitted to
arbitration generally in accordance with the procedures set forth in Article 12 of this Agreement, and the arbitrator shall base his/her decision on the above factors. 
 (d) By Trimeris For Cause. In the event of termination of this Agreement by Trimeris under Section 10.3, (i) all licenses granted by Trimeris to Roche shall terminate, (ii) at the
request of Trimeris, Roche shall assign to Trimeris all regulatory filings, regulatory approvals and clinical data owned and controlled by Roche relating to Products, or, if such assignment is not legally permissible, grant Trimeris the right to
access, use and cross reference such filings, approval and data, and (iii) Roche shall assign to Trimeris all rights in the trademarks referred to in Section 6.2. 
 10.5 Return of Product to Trimeris. In the event that Trimeris requests the assignment of any regulatory filings, regulatory approvals or clinical data pursuant to subsection 10.4(d) (but, for the
avoidance of doubt, not in the event that Trimeris requests the assignment of regulatory filings, regulatory approvals or clinical data pursuant to subsection 10.4(a)), then Trimeris shall pay Roche a royalty upon sales of Product reasonably related
to such assigned filings, approvals or data; provided that, this Section 10.5 shall not apply (i.e., no royalty shall be payable by Trimeris to Roche following termination, whether based on assigned regulatory filings, regulatory
approvals or clinical data or otherwise) in the event that Trimeris terminates this Agreement pursuant to Section 10.3 based on Roche’s deliberate breach of its obligations under Section 6.1 with respect to four (4) or more of
the top 

  
 -30-

 
eight (8) major countries of the world as determined by market size for HIV and AIDS drugs. The amount of such royalty shall be determined by mutual agreement of the parties after good faith
negotiation; provided, however, that if the parties are unable to reach mutual agreement thereon, the matter shall be submitted to arbitration generally in accordance with the procedures set forth in Article 12 of this Agreement, and the arbitrator
shall base his/her decision on the following factors: (i) the value of the assigned filings, approvals and/or data as related to the commercialization of Product; (ii) the relative contributions of the parties to the development of
Product. 
 10.6 Survival. Notwithstanding any termination of this Agreement, the obligations of the Parties with respect to audit under
Section 7.8 and Information under Article 8, payment obligations that have accrued hereunder prior to the time of such termination, as well as any other provisions which by their nature are intended to survive any such termination, shall
survive and continue to be enforceable. 
  

	11.	WARRANTIES AND INDEMNITIES 

 11.1
Trimeris Warranties. 
 (a) Trimeris warrants and represents that, as of the date Trimeris signs this Agreement and to
the best of its knowledge, it has the entire right, title and interest to make, have made, use, offer for sale, sell and import the Compound enfuvirtide and/or the Product sold under the brand name Fuzeon®; and that it has no knowledge of the
existence of any patent or patent application other than the patents involved in the Novartis Settlement owned or controlled by anyone other than Trimeris which could be asserted to claim the Compound enfuvirtide and/or the Product sold under the
brand name Fuzeon® and/or could be asserted to prevent Trimeris or Roche from importing, making, having made, using, offering to sell, or selling such Compound and/or such Product. 

  
 -31-

 (b) Trimeris warrants and represents that it has identified on Appendix A all of the patents
or patent applications that, as of the date Trimeris signs this Agreement, it owns or licenses which, in its reasonable opinion, would preclude Roche from making, having made, using, offering for sale, selling or importing Product sold under the
brand name Fuzeon® for any use. 
 11.2 Warranties of Both Parties. The Parties each make the representations and warranties set
forth in this Article 11. In making the representations and warranties that apply to any or all Parties, each Party is making such representations and warranties as to itself and is not making such representations and warranties jointly with any
other Party. 
 a. Each Party represents and warrants that (i) it has the full legal right and power to enter into, and
perform the transactions contemplated by, this Agreement, without need for any consent, approval, authorization, license or order of, or notice to or filing with, any other Person; (ii) the execution, delivery and performance by such Party of
this Agreement and the consummation by such Party of the transactions contemplated hereby have been duly and validly authorized and approved by all necessary managing and governing bodies of such Party, including approval of this Agreement by the
Board of Directors and stockholders of such Party or the trustees of the Party, if required; (iii) this Agreement evidences the legal, valid and binding obligations of such Party, enforceable against such Party in accordance with its terms; and
(iv) this Agreement has been duly executed and delivered by such Party. 
 b. Each Party represents and warrants that as of
the Effective Date it has not filed (or caused to be filed through a third party) any legal or administrative proceeding of any kind or nature anywhere in the world relating to the Previous Agreement. 

  
 -32-

 c. Each Party represents and warrants that it has received or had the opportunity to obtain
independent legal advice from such Party’s attorneys with respect to the rights and obligations arising from, and the advisability of executing, this Agreement. 
 11.3 DISCLAIMER. THE FOREGOING REPRESENTATIONS AND WARRANTIES ARE IN LIEU OF ALL OTHER REPRESENTATIONS AND WARRANTIES NOT EXPRESSLY SET FORTH HEREIN. TRIMERIS AND ROCHE DISCLAIM ALL OTHER
WARRANTIES, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO EACH OF THEIR RESEARCH, DEVELOPMENT AND COMMERCIALIZATION EFFORTS HEREUNDER, INCLUDING, WITHOUT LIMITATION, WHETHER THE PRODUCTS CAN BE SUCCESSFULLY DEVELOPED OR MARKETED, THE ACCURACY,
PERFORMANCE, UTILITY, RELIABILITY, TECHNOLOGICAL OR COMMERCIAL VALUE, COMPREHENSIVENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE WHATSOEVER OF THE PRODUCTS. IN NO EVENT SHALL EITHER TRIMERIS OR ROCHE BE LIABLE FOR SPECIAL, INDIRECT,
INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THIS AGREEMENT BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY. 
 11.4 Indemnification
by Roche. Roche agrees to defend, indemnify and hold Trimeris and its directors, officers, employees and agents (the “Trimeris indemnified parties”) harmless from and against any losses, costs, and damages, including reasonable costs
and expenses arising out of the development, manufacture, use, sale or other disposition of any Product by Roche, its Affiliates, its sublicensees, its distributors, or representatives, except to the extent that such losses, costs and damages are
due to the negligence or wrongful acts or failures to act of Trimeris. In the event of any such claim against the Trimeris indemnified parties by a third party, Trimeris shall promptly notify Roche in writing of the claim and Roche shall

  
 -33-

 
undertake and shall solely manage and control, at its sole expense, the defense of the claim and its settlement. The Trimeris indemnified parties shall cooperate with Roche and may, at their
option and expense, be represented in any such action or proceeding. Roche shall not be liable for any litigation costs or expenses incurred by the Trimeris indemnified parties without Roche’s written authorization. Roche shall not settle any
such claim against Trimeris unless such settlement fully and unconditionally releases Trimeris from all liability relating thereto, unless Trimeris otherwise agrees in writing. 
 11.5 Indemnification by Trimeris. Trimeris agrees to defend, indemnify and hold Roche and its directors, officers, employees and agents (the “Roche indemnified parties”) harmless from and
against any losses, costs, and damages, including reasonable costs and expenses arising out of the development, manufacture, use, sale or other disposition of any Product by Trimeris, its Affiliates, licensees (other than Roche), distributors, or
representatives (if applicable), except to the extent that such losses, costs and damages are due to the negligence or wrongful acts or failures to act of Roche. In the event of any such claim against the Roche indemnified parties by a third party,
Roche shall promptly notify Trimeris in writing of the claim and Trimeris shall undertake and shall solely manage and control, at its sole expense, the defense of the claim and its settlement. The Roche indemnified parties shall cooperate with
Trimeris and may, at their option and expense, be represented in any such action or proceeding. Trimeris shall not be liable for any litigation costs or expenses incurred by the Roche indemnified parties without Trimeris’ written authorization.
Trimeris shall not settle any such claim against Roche unless such settlement fully and unconditionally releases Roche from all liability relating thereto, unless Roche otherwise agrees in writing. 

  
 -34-

 ARTICLE 12. DISPUTE RESOLUTION 
 12.1 Procedure 
 (a) Internal Escalation. Unless otherwise
explicitly set forth in this Agreement, in the event that the Parties are unable to resolve any dispute, controversy or claim arising out of, or in relation to this Agreement, or the breach, termination or invalidity thereof (collectively
“Issue”), the Parties shall first refer such Issue to the Head of Roche Partnering and to the Chief Executive Officer of Trimeris. In the event that such Issue cannot be resolved by these individuals after a good faith discussion to
resolve the issue, then either Party may initiate arbitration in accordance with this subsection under the guidelines of AAA in New York City, New York, under the commercial rules then in effect for AAA, except as provided for herein. 

(b) Procedure. A Party shall notify the other in writing should it intend to initiate arbitration. The Parties shall select, by
mutual agreement, one arbitrator within a time period of thirty (30) days after receipt of such notice. Should no arbitrator be chosen within the above period, the AAA shall appoint the arbitrator within thirty (30) days after the end of
such period. Within thirty (30) days after selection of such arbitrator, each Party shall submit to the arbitrator a proposed resolution of the Issue and the reasons for proposing the resolution. Should either Party desire, a joint meeting
before the arbitrator shall be held within thirty (30) days after the end of the above resolution submission period. 
 Within thirty
(30) days after the later of (i) the end of the resolution submission period or (ii) holding of the joint meeting, the arbitrator shall decide the matter by selecting only one of such resolutions, and shall have no authority to modify
its proposed terms. 
 (c) Unless otherwise agreed to by the Parties, the arbitrator shall make such decision based on the
following factors in descending order of importance: (a) consistency with the provisions of this Agreement; (b) consistency with the intent of the Parties as reflected in this Agreement; and (c) customary and reasonable

  
 -35-

 
provisions included in comparable agreements. The decision of the arbitrator will be binding upon the Parties without the right of appeal, and judgment upon the decision rendered by the
arbitrator may be entered in any court having jurisdiction thereof. 
 12.2 Cost. The Parties shall share equally the reasonable
documented cost of such arbitration proceeding, but not the individual cost of the Parties in participating in such proceeding. 
  

	13.	MISCELLANEOUS 

 13.1 Disclosure
of Agreement and Press Releases and Technical Information. Neither Party will disclose the existence, terms or conditions of this Agreement to any third party or issue any press release relating to the existence, terms and conditions of this
Agreement for any purpose without the prior written consent of the other Party, except as required by law (including without limitation any regulatory agency, such as the SEC, or commission of competent jurisdiction). 

13.2 Force Majeure. If either Party shall be delayed, interrupted or prevented with respect to the performance of any obligation hereunder by
reason of an act of God, fire, flood, war (declared or undeclared), public disaster, strike or labor dispute, governmental enactment, rule or regulation, or any similar cause beyond such Party’s control, such Party shall not be liable to the
other therefor; and the time for performance of such obligation shall be extended for a period equal to the duration of the contingency which occasioned the delay, interruption or prevention. 
 Within fifteen (15) days after the beginning of the force majeure, the Party invoking its force majeure rights must notify the other Party of this fact in accordance with Section 13.5. The other
Party must also be notified of the termination of the force majeure within fifteen (15) days after such termination. If the force majeure renders either of the required notifications impossible, notification must be given as soon as possible.

  
 -36-

 13.3 Bankruptcy. In the event that Trimeris shall become insolvent, shall make an assignment to the
benefit of creditors, or shall have a petition in bankruptcy filed for or against it (which, in the case of an involuntary petition, is not dismissed or stayed within sixty (60) days after such petition is filed), all rights and licenses
granted under or pursuant to this Agreement by Trimeris to Roche are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11, US Code (the “Bankruptcy Code”), licenses of rights to “intellectual
property” as defined under Section 101(60) of the Bankruptcy Code. The Parties agree that Roche, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy
Code, subject to the continued performance of its obligations under this Agreement. 
 13.4 Waiver. The waiver by a Party of a breach or
a default of any provision of this Agreement by the other Party shall not be construed as a waiver of any succeeding breach of the same or any other provision, nor shall any delay or omission on the part of a Party to exercise or avail itself of any
right, power or privilege that it has or may have hereunder operate as a waiver of any right, power or privilege by such Party. 
 13.5
Notices. Any notice or communication (including invoices) required to be given hereunder shall be in writing and shall be considered properly given when (a) personally delivered or sent by telefax (other than for invoices) or overnight
mail with a confirmation copy, (b) three (3) business days after being sent by certified or registered mail to the respective address of a Party, or (c) the next business day after being sent by overnight mail or overnight courier as
follows: 
  

			
	If to Roche:	    	F. Hoffmann-La Roche Ltd
		    	Grenzacherstrasse 124
		    	CH-4070 Basel Switzerland
		    	Att.: Corporate Law

  
 -37-

			
		
	 and
	    	
		
		    	Hoffmann-La Roche Inc.
		    	430 Kingsland Street
		    	Nutley, New Jersey 70110, USA
		    	Attn.: Corporate Secretary

 or any other
address that Roche may advise in writing; 
  

			
	If to Trimeris:	    	Trimeris, Inc.
		    	2530 Meridian Parkway, Second Floor
		    	Durham, North Carolina 27713, USA
		    	Attn.: CEO

 or any other address that
Trimeris may advise in writing. 
 13.6 No Agency. Nothing herein shall be deemed to constitute either Party as the agent or
representative of the other Party. Each Party shall be an independent contractor, not an employee or partner of the other Party. Each Party shall be responsible for the conduct of activities at its own facilities and for any liabilities resulting
therefrom. Neither Party shall be responsible for the acts or omissions of the other Party, and neither Party will have authority to speak for, represent or obligate the other Party in any way without prior written authority from the other Party.

 13.7 Entire Agreement. This Agreement (including its Appendix) constitutes the entire agreement between the Parties with respect to
the subject matter of this Agreement and supersedes all previous agreements, whether oral or written, including the Previous Agreement. This Agreement can only be changed or modified by written agreement of the Parties. 

  
 -38-

 13.8 Captions. The captions herein are for convenience only and shall not be interpreted as having
any substantive meaning. 
 13.9 Severability. In the event that any provision of this Agreement is held by a court of competent
jurisdiction to be unenforceable because it is invalid or in conflict with any law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the Parties shall negotiate a substitute provision that, to the
extent possible, accomplishes the original business purpose. 
 13.10 Assignment. Each Party shall have the right, upon notice to the
other Party, to assign this Agreement to an Affiliate or, in the case of a sale or transfer by such Party of all or substantially all of its business or assets relating to the subject matter of this Agreement, whether by merger, sale of stock, sale
of assets or otherwise, to the purchaser or transferee of all or substantially all of such business or assets, but this Agreement shall otherwise not be assignable without prior written consent of the other Party. This Agreement shall be binding
upon and shall inure to the benefit of successors and permitted assigns of the Parties hereto, provided that the assigning Party shall remain primarily liable for the performance of its obligations hereunder and shall require that any assignee agree
to be bound by the terms and obligations of this Agreement. 
 13.11 Law. This Agreement will be interpreted in accordance with the laws
of the state of New York. 
 13.12 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be
deemed an original but all of such together shall constitute one and the same instrument. 

  
 -39-

 IN WITNESS WHEREOF, Trimeris and Roche have caused this Agreement to be duly executed by
their authorized representatives on the dates written below. 
  

									
	Trimeris, Inc.	 		 	Hoffmann-La Roche Inc.
					
	By:	 	 /s/ Martin Mattingly
	 		 	By:	 	 /s/ Ivor Macleod

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 Vice President and Chief Financial Officer

					
	Date:	 	 May 25, 2011
	 		 	Date:	 	 May 25, 2011

			
	F. Hoffmann-La Roche Ltd	 		 	
					
	By:	 	 /s/ Christop Sorry
	 		 	By:	 	 /s/ Stefan Arnold

					
	Title:	 	 Global Alliance Director
	 		 	Title:	 	 Head Legal Pharma

					
	Date:	 	 May 25, 2011
	 		 		 	

  
 -40-

 Appendix A 

Trimeris Patents 
 List of U.S. and Canadian T-20 Patents and Expiration Dates 
  

							
	 Patent No.
	  	Issue Date	  	 Title
	  	Expiration
Date
				
	U.S. Pat. No. 5,464,933	  	11/7/95	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2013
				
	U.S. Patent No. 6,133,418	  	10/17/00	  	Synthetic Peptide Inhibitors of HIV Transmission	  	11/17/2014
				
	U.S. Patent No. 6,475,491	  	11/5/02	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/7/2015
				
	U.S. Patent No. 6,861,059	  	3/1/05	  	Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations	  	9/9/2015
				
	Canadian Patent No. 2,224,008	  	8/18/09	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/6/2016
				
	U.S. Patent No. 6,281,331	  	8/28/01	  	Methods and Compositions for Peptide Synthesis	  	3/23/2018
				
	U.S. Patent No. 6,015,881	  	1/18/00	  	Methods and Compositions for Peptide Synthesis	  	3/23/2018
				
	U.S. Patent No. 6,824,783	  	11/30/04	  	Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission	  	11/30/2021

  
 -41-

 List of T-20 Non-US or Canadian Patents and Expiration Dates 

 

							
	 Country/Patent No.
	  	Issue Date	  	 Title
	  	Expiration
				
	Chile Patent No. 1413-2004	  	11/25/09	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2013
				
	Australia Patent No. 692777	  	11/5/98	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2014
				
	Japan Patent No. 4205159	  	10/24/08	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2014
				
	Monaco Patent No. 0774971	  	4/13/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2014
				
	New Zealand Patent No. 267803	  	7/8/99	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2014
				
	S. Korea Patent No. 0355407	  	9/24/02	  	Synthetic Peptide Inhibitors of HIV Transmission	  	6/7/2014
				
	Australia Patent No. 723537	  	12/14/00	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/6/2016
				
	Mexico Patent No. 256541	  	4/22/08	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/6/2016
				
	New Zealand Patent No. 311319	  	5/12/00	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/6/2016
				
	S. Korea Patent No. 0571215	  	4/7/06	  	Treatment of HIV and Other Viral Infections Using Combinatorial Therapy	  	6/6/2016
				
	Austria Patent No. 0774971	  	1/19/06	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018

  
 -42-

							
	 Country/Patent No.
	  	Issue Date	  	 Title
	  	Expiration
				
	Belgium Patent No. 0774971	  	6/2/07	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	Denmark Patent No. 0774971	  	5/5/08	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	France Patent No. 0774971	  	10/30/09	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	Germany Patent No. 69434335	  	9/26/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	5/27/2018
				
	Greece Patent No. 3053602	  	9/21/06	  	Synthetic Peptide Inhibitors of HIV Transmission	  	5/1/2018
				
	Ireland Patent No. 0774971	  	4/9/09	  	Synthetic Peptide Inhibitors of HIV Transmission	  	9/24/2018
				
	Italy Patent No. 0774971	  	9/20/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	Luxembourg Patent No. 0774971	  	6/20/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	Netherlands Patent No. 0774971	  	6/13/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/29/2018
				
	Portugal Patent No. 0774971	  	8/9/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	5/1/2018
				
	Spain Patent No. 0774971	  	12/23/08	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/30/2018
				
	Sweden Patent No. 0774971	  	10/0/06	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/29/2018
				
	Switzerland Patent No. 0774971	  	2/29/08	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/29/2018

  
 -43-

							
	 Country/Patent No.
	  	Issue Date	  	 Title
	  	Expiration
				
	UK Patent No. 0774971	  	9/5/05	  	Synthetic Peptide Inhibitors of HIV Transmission	  	4/29/2018
				
	Australia Patent No. 751358	  	11/28/02	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Austria Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Belgium Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	China Patent No. Z199806431.9	  	4/23/08	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Denmark Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	France Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Germany Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	India Patent No. 224303	  	10/10/08	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Ireland Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Italy Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Japan Patent No. 4602547	  	10/8/10	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Mexico Patent No. 254761	  	2/15/08	  	Methods and Compositions for Peptide Synthesis	  	3/22/19

  
 -44-

							
	 Country/Patent No.
	  	Issue Date	  	 Title
	  	Expiration
				
	Netherlands Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	New Zealand Patent No. 507083	  	2/9/04	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	South Korea Patent No. 0633214	  	9/29/06	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Spain Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Switzerland Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19
				
	Taiwan Patent No. I233931	  	6/11/05	  	Methods and Compositions for Peptide Synthesis	  	3/23/19
				
	United Kingdom Patent No. 1071442	  	7/6/05	  	Methods and Compositions for Peptide Synthesis	  	3/22/19

  
 -45-Form of Director Indemnification Agreement

 Exhibit 10.2 
 INDEMNIFICATION AGREEMENT 
 THIS INDEMNIFICATION AGREEMENT (this
“Agreement”) is made and entered into as of May     , 2011, by and among TRIMERIS, INC., a Delaware corporation (the
“Company”) and                      (the “Indemnitee”). 

RECITALS 

WHEREAS, the Company values Indemnitee’s service to the Company as a member of the Board of Directors of the Company (the
“Board”) and desires that Indemnitee continue to serve the Company in such capacity; 
 WHEREAS,
Indemnitee does not regard the protection available under the organizational documents of the Company and any insurance policies maintained by the Company as adequate in the present circumstances, and Indemnitee may not be willing to continue to
serve in his capacity as a director of the Company without the additional protections set forth in this Agreement; 

WHEREAS, the Board has determined that, on the basis of the foregoing, it is reasonable, prudent and necessary for the Company to
obligate itself contractually to indemnify, and to advance expenses on behalf of, Indemnitee as set forth in this Agreement so that Indemnitee will serve or continue to serve the Company free from undue concern that he will not be so indemnified;
and 
 WHEREAS, this Agreement is a supplement to and in furtherance of the organizational documents of the Company and
any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; 
 NOW, THEREFORE, in consideration of the mutual promises and agreements herein contained, and intending to be legally bound, the parties hereto agree as follows: 

AGREEMENT 

1. INDEMNIFICATION OF INDEMNITEE. 

(a) The Company shall not amend the Certificate of Incorporation or Bylaws (as each may be amended from time to time) of the
Company in any way that adversely affects Indemnitee’s rights to indemnification thereunder, as such rights exist on the date hereof and the Company agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by applicable
law, as such may be amended from time to time. 
 (b) In furtherance of the indemnification provided in
Section 1(a) and without limiting the generality thereof, in the event Indemnitee, by reason of his Corporate Status (as defined in Section 13(a)), is, or is threatened to be made, a party to or participant in any Proceeding
(as defined in Section 13(f)), including any Proceeding brought by or in the right of the Company, the Company shall hold harmless and indemnify Indemnitee against all Expenses (as defined in Section 13(d)), judgments,
penalties, fines and amounts paid in settlement actually and reasonably incurred by him, or on his behalf, in connection with such Proceeding or any matter therein, provided that Indemnitee acted in good faith and in a manner Indemnitee reasonably
believed to be in or not opposed to the best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. 

(c) Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a
party to and is successful, on the merits or otherwise, in any Proceeding, the Company shall hold harmless and indemnify Indemnitee against all Expenses actually 

 
and reasonably incurred by him or on his behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding, but is successful on the merits or otherwise, as to one or more
but less than all claims, issues or matters in such Proceeding, the Company shall hold harmless and indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved
claim, issue or matter. For purposes of this Section 1(c) and without limitation, the termination of any claim, issue or matter in a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such
claim, issue or matter. 
 2. LIMITATION ON INDEMNITY. The Company shall not be obligated to
make any payment to Indemnitee under this Agreement that is finally determined (under the procedures, and subject to the presumptions, set forth in Section 6 and Section 7 hereof) to be unlawful. 

3. CONTRIBUTION. 
 (a) Whether or not the indemnification provided in Section 1 hereof is available, in respect of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if
joined in such Proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such Proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes
any right of contribution it may have against Indemnitee. The Company shall not enter into any settlement of any Proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such Proceeding) unless such settlement
provides for a full and final release of all claims asserted against Indemnitee. 
 (b) Without diminishing or impairing
the obligations of the Company set forth in Section 3(a), if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any Proceeding in which the Company is jointly liable with
Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred and paid or payable by Indemnitee in proportion to the
relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the
other hand, from the transaction from which such Proceeding arose; provided, however, that the proportion determined on the basis of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to
the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, in
connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as any other equitable considerations which applicable law may require to be considered. The relative fault of the Company and all officers,
directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would be if joined in such Proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other
things, the degree to which their actions were motivated by intent to gain personal profit or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive. 

(c) The Company hereby agrees to fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought
by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee. 

(d) To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable
to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or
for Expenses, in connection with any Proceeding relating to an indemnifiable event under this Agreement, in such proportion as is 

 
deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect: (i) the relative benefits received by the Company and Indemnitee as a result of the
event(s) and/or transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s). 

4. INDEMNIFICATION FOR EXPENSES OF A WITNESS.
Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness, or is made (or asked) to respond to discovery requests, in any Proceeding to which Indemnitee is not a party, the
Company shall hold harmless and indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith. 
 5. ADVANCEMENT OF EXPENSES. Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on
behalf of Indemnitee in connection with any Proceeding by reason of Indemnitee’s Corporate Status within fourteen (14) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances
from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written undertaking by
or on behalf of Indemnitee to repay any Expenses advanced if it shall ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses. Any advances and undertakings to repay pursuant to this Section 5
shall be unsecured and interest free. 
 6. PROCEDURES AND PRESUMPTIONS
FOR DETERMINING ENTITLEMENT TO INDEMNIFICATION. It is the intent of this Agreement to secure for Indemnitee rights of indemnification that are at least as favorable as
may be permitted under applicable law. Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this Agreement: 

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or
therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon
receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification. Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request
in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to the extent that, such failure actually and materially prejudices the interests of the Company. 

(b) Upon written request by Indemnitee for indemnification pursuant to the first sentence of Section 6(a) hereof, a
determination with respect to Indemnitee’s entitlement thereto shall be made in the specific case by one of the following four methods, which shall be at the election of the Board: (i) by a majority vote of the Disinterested Directors (as
defined in Section 13(b)), even though less than a quorum; (ii) by a committee of those Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum; (iii) if there are no
Disinterested Directors or if the Disinterested Directors so direct, by independent legal counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (iv) if so directed by the Board, by the stockholders of
the Company. 
 (c) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant
to Section 6(b) hereof, the Independent Counsel shall be selected as provided in this Section 6(c). The Independent Counsel shall be selected by the Board and written notice of such selection shall be provided to Indemnitee within two
business days thereafter. Indemnitee may, within 10 days after such written notice of selection shall have been given, deliver to the Company a written objection to 

 
such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent
Counsel” (as defined in Section 13(e)), and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If a
written objection is made and substantiated, the Independent Counsel selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit. If, within 20 days after
submission by Indemnitee of a written request for indemnification pursuant to Section 6(a) hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent
jurisdiction for resolution of any objection which shall have been made by Indemnitee to the Company’s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person
as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 6(b) hereof. The Company shall pay any and all fees, costs and expenses
of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to Section 6(b) hereof, and the Company shall pay all fees, costs and expenses incident to the procedures of this Section 6(c), regardless of
the manner in which such Independent Counsel was selected or appointed. 
 (d) In making a determination with respect to
entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement. Anyone seeking to overcome this presumption shall have the burden
of proof and the burden of persuasion by clear and convincing evidence. Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement of any action pursuant to
this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent legal counsel) that Indemnitee
has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct. 
 (e) Indemnitee shall be deemed to have acted in good faith if Indemnitee’s action is based on the records or books of account of the Enterprise (as defined in Section 13(c)),
including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the
Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of
the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 6(e) are satisfied, it shall in any event be
presumed that Indemnitee has at all times acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the
burden of persuasion by clear and convincing evidence. 
 (f) If the person, persons or entity empowered or selected
under this Section 6 to determine whether Indemnitee is entitled to indemnification shall not have made a determination within thirty (30) days after receipt by the Company of the request therefor, the requisite determination of
entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent: (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make
Indemnitee’s statement not materially misleading, in connection with the request for indemnification; or (ii) a prohibition of such indemnification under applicable law; provided, however, that such 30-day period may be
extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith requires such additional time to obtain or
evaluate documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this Section 6(f) shall 

 
not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to Section 6(b) of this Agreement and if (A) within fifteen
(15) days after receipt by the Company of the request for such determination, the Board or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual meeting
thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such
determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat. 
 (g) Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person,
persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any
Independent Counsel, member of the Board or stockholder of the Company shall act reasonably and in good faith in making a determination regarding Indemnitee’s entitlement to indemnification under this Agreement. All fees, costs and expenses
(including attorneys’ fees and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s
entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. 

(h) The Company acknowledges that a settlement or other disposition short of final judgment may be successful if it permits a
party to avoid expense, delay, distraction, disruption and uncertainty. In the event that any Proceeding to which Indemnitee is a party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation,
settlement of such Proceeding with or without payment of money or other consideration) it shall be presumed that Indemnitee has been successful on the merits or otherwise in such Proceeding. Anyone seeking to overcome this presumption shall have the
burden of proof and the burden of persuasion by clear and convincing evidence. 
 (i) The termination of any Proceeding
or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of
Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding,
that Indemnitee had reasonable cause to believe that his conduct was unlawful. 
 7. REMEDIES OF
INDEMNITEE. 
 (a) In the event that: (i) a determination is made pursuant to
Section 6 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement; (ii) advancement of Expenses is not timely made pursuant to Section 5 of this Agreement; (iii) no determination of
entitlement to indemnification is made pursuant to Section 6(b) of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification; (iv) payment of indemnification is not made pursuant to
this Agreement within ten (10) days after receipt by the Company of a written request therefor; or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to
indemnification or such determination is deemed to have been made pursuant to Section 6 of this Agreement, Indemnitee shall be entitled to an adjudication in any court of competent jurisdiction of Indemnitee’s entitlement to such
indemnification. The Company shall not oppose Indemnitee’s right to seek any such adjudication. 
 (b) In the event
that a determination shall have been made pursuant to Section 6(b) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced 

 
pursuant to this Section 7 shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under
Section 6(b). 
 (c) If a determination shall have been made pursuant to Section 6(b) of this
Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant to this Section 7, absent: (i) a misstatement by Indemnitee of a material fact
or an omission of a material fact necessary to make Indemnitee’s misstatement not materially misleading in connection with the application for indemnification; or (ii) a prohibition of such indemnification under applicable law. 

(d) In the event that Indemnitee, pursuant to this Section 7, seeks a judicial adjudication of his rights under, or to
recover damages for breach of, this Agreement, or to recover under any directors’ and officers’ liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types
described in the definition of “Expenses” in Section 13(d) of this Agreement) actually incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such
indemnification, advancement of expenses or insurance recovery. 
 (e) The Company shall be precluded from asserting in
any judicial proceeding commenced pursuant to this Section 7 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is bound by all the
provisions of this Agreement. The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent
not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of Expenses from the Company under this Agreement or under any directors’
and officers’ liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of Expenses or insurance recovery, as the case may be.

 (f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification
under this Agreement shall be required to be made prior to the final disposition of the Proceeding. 
 8.
NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; ETC. 
 (a) The rights of indemnification as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the
organizational documents of the Company, any other agreement with the Company, a vote of the Company’s stockholders, a resolution of the Board or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall
limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in any applicable law,
whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the Company’s organizational documents and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by
this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right
and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or
remedy. 

 (b) To the extent that the Company maintains an insurance policy or policies
providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent
of the coverage available for any director, officer, employee, agent or fiduciary under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has directors’ and officers’
liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or
desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 
 9. EXCEPTION TO RIGHT OF INDEMNIFICATION. Notwithstanding any provision in this Agreement, the Company shall not be
obligated under this Agreement to provide any indemnification in connection with any claim made against Indemnitee: (i) for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity
provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; (ii) for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of
the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law; or (iii) in connection with any Proceeding (or any part of any Proceeding)
initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company (other than a Proceeding to enforce Indemnitee’s rights under this Agreement) or its directors, officers, employees or
other indemnitees, unless (A) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (B) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company
under applicable law; it being understood that a counterclaim or cross-complaint by Indemnitee shall not be deemed the initiation of a Proceeding by Indemnitee. 
 10. DURATION OF AGREEMENT. All agreements and obligations of the Company contained herein shall continue until the date that is six
(6) years after the date upon which Indemnitee’s Corporate Status terminates and shall continue thereafter so long as Indemnitee shall be subject to any Proceeding (or any proceeding commenced under Section 7 hereof) by reason
of his Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement. This Agreement shall be binding upon and inure to
the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the
Company), assigns, spouses, heirs, executors and personal and legal representatives. 
 11. SECURITY. To the extent
requested by Indemnitee and approved by the Board, the Company may at any time and from time to time provide security to Indemnitee for the Company’s obligations hereunder through an irrevocable bank line of credit, funded trust or other
collateral. Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of Indemnitee. 

12. ENFORCEMENT. The Company expressly confirms and agrees that it has entered into this Agreement and assumes the
obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as an officer or director of the Company.

 13. DEFINITIONS. For purposes of this Agreement: 

(a) “Corporate Status” describes the status of a person who is or was at any time (including, without
limitation, any time prior to the date of this Agreement) a director, officer, employee, agent or 

 
fiduciary of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the request of, or on
behalf of, the Company. 
 (b) “Disinterested Director” means a director of the Company who is
not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee. 
 (c)
“Enterprise” shall mean the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the request of, or otherwise on behalf of, the
Company as a director, officer, employee, agent or fiduciary. 
 (d) “Expenses” shall include all
reasonable attorneys’ fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other disbursements
or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or preparing to be a witness in a Proceeding, or responding to, or objecting to, a
request to provide discovery in any Proceeding. Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual
or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent. 

(e) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of
corporation law and neither presently is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this
Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent
Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s
rights under this Agreement. The Company agrees to pay the reasonable fees of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to
this Agreement or its engagement pursuant hereto. 
 (f) “Proceeding” includes any threatened,
pending or completed claim, action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding (including one pending on or before the date of
this Agreement), whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, as a result of Indemnitee’s
Corporate Status with the Company, by reason of any action taken by him or of any inaction on his part while acting as an officer or director of the Company, or by reason of the fact that he is or was serving at the request of the Company as a
director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise, in each case whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred
for which indemnification can be provided under this Agreement. 
 14. SEVERABILITY. The invalidity or
unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision. Without limiting the generality of the foregoing, this Agreement is intended to confer upon Indemnitee indemnification rights to
the fullest extent permitted by applicable laws. In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with the aforementioned intent, to the extent necessary to resolve such
conflict. 

 15. MODIFICATION AND WAIVER. No supplement,
modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. 
 16. NOTICE
BY INDEMNITEE. Indemnitee agrees to promptly notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other document relating
to any Proceeding or matter which may be subject to indemnification covered hereunder. The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise unless and
only to the extent that such failure or delay materially prejudices the Company. 
 17. NOTICES. All notices and
other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed electronic mail or facsimile if
sent during normal business hours of the recipient, and if not so confirmed, then on the next business day; (iii) five (5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(iv) one business (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All notices and other communications shall be sent: 

(a) To Indemnitee at the address set forth below Indemnitee’s signature hereto. 

(b) To the Company at: 
 Trimeris, Inc. 
 2530 Meridean Parkway, 2nd Floor 

Durham, NC 27713 

Attention: Board of Directors 

or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be. 

18. HEADINGS. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof. 
 19. GOVERNING LAW. This
Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules 

20. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement between the parties hereto with respect
to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof 
 21. COUNTERPARTS. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same Agreement. This Agreement may also be executed and delivered by facsimile signature (or other similar electronic means) and in two (2) or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on and as of the
day and year first written above. 
  

			
	COMPANY:
	
	TRIMERIS, INC.
	
	  

	Name:	 	
	Title:	 	
	
	INDEMNITEE:
	
	  

	Name	 	
		
	Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]